Ash Zawerton1, Cyril Mignot2,3, Ashley Sigafoos4, Patrick R Blackburn5, Abdul Haseeb6, Kirsty McWalter7, Shoji Ichikawa8, Caroline Nava2,3, Boris Keren2,3, Perrine Charles3, Isabelle Marey3, Anne-Claude Tabet9,10, Jonathan Levy9, Laurence Perrin9, Andreas Hartmann2,11, Gaetan Lesca12,13, Caroline Schluth-Bolard12,13, Pauline Monin12, Sophie Dupuis-Girod12,14, Maria J Guillen Sacoto7, Rhonda E Schnur7, Zehua Zhu7, Alice Poisson15, Salima El Chehadeh16, Yves Alembik16, Ange-Line Bruel17,18, Daphné Lehalle17,19, Sophie Nambot17,19, Sébastien Moutton17,19, Sylvie Odent20,21, Sylvie Jaillard22, Christèle Dubourg21,23, Yvonne Hilhorst-Hofstee24, Tina Barbaro-Dieber25, Lucia Ortega25, Elizabeth J Bhoj26, Diane Masser-Frye27, Lynne M Bird27,28, Kristin Lindstrom29, Keri M Ramsey30, Vinodh Narayanan30, Emily Fassi31, Marcia Willing31, Trevor Cole32, Claire G Salter32,33, Rhoda Akilapa34, Anthony Vandersteen35, Natalie Canham36,37, Patrick Rump38, Erica H Gerkes38, Jolien S Klein Wassink-Ruiter38, Emilia Bijlsma38, Mariëtte J V Hoffer24, Marcelo Vargas39,40, Antonina Wojcik39,40, Florian Cherik41, Christine Francannet41, Jill A Rosenfeld42, Keren Machol42, Daryl A Scott42,43, Carlos A Bacino42, Xia Wang42, Gary D Clark44, Marta Bertoli45, Simon Zwolinski45, Rhys H Thomas46,47, Ela Akay47, Richard C Chang48, Rebekah Bressi48, Rossana Sanchez Russo49, Myriam Srour50, Laura Russell51, Anne-Marie E Goyette52, Lucie Dupuis53, Roberto Mendoza-Londono53, Catherine Karimov54, Maries Joseph55, Mathilde Nizon56,57, Benjamin Cogné56,57, Alma Kuechler58, Amélie Piton59,60, Eric W Klee5,61, Véronique Lefebvre62, Karl J Clark4, Christel Depienne63,64,65. 1. Department of Cellular & Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA. 2. INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France. 3. AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique; Centre de Référence Déficiences Intellectuelles de Causes Rares, GRC UPMC « Déficience Intellectuelle et Autisme », Paris, France. 4. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA. 5. Center for Individualized Medicine, Department of Health Science Research, and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 6. Department of Surgery, Division of Orthopaedic Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 7. GeneDx, Gaithersburg, MD, USA. 8. Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, CA, USA. 9. Genetics Department, Robert Debré Hospital, APHP, Paris, France. 10. Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France. 11. APHP, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France. 12. Service de Génétique, Hospices Civils de Lyon - GHE, Lyon, France. 13. CNRS UMR 5292, INSERM U1028, CNRL, and Université Claude Bernard Lyon 1, GHE, Lyon, France. 14. Centre de référence pour la maladie de Rendu-Osler, Bron, France. 15. GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (CNRS & Lyon 1 Claude Bernard University), Lyon, France. 16. Département de Génétique Médicale, CHU de Hautepierre, Strasbourg, France. 17. INSERM 1231 LNC, Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, France. 18. FHU-TRANSLAD, Université de Bourgogne/CHU Dijon, Dijon, France. 19. Centre de Génétique et Centre de Référence Maladies Rares «Anomalies du Développement de l'Interrégion Est», Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France. 20. CHU de Rennes, service de génétique clinique, Rennes, France. 21. Univ Rennes, CNRS, IGDR, UMR 6290, Rennes, France. 22. Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France. 23. Service de Génétique Moléculaire et Génomique, CHU, Rennes, France. 24. Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands. 25. Cook Childrens Medical Center, Fort Worth, TX, USA. 26. Department of Clinical Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 27. Rady Children's Hospital San Diego, Division of Genetics and Dysmorphology, San Diego, CA, USA. 28. Department of Pediatrics, University of California-San Diego, San Diego, CA, USA. 29. Division of Genetics and Metabolism, Phoenix Children's Hospital, Phoenix, AZ, USA. 30. Translational Genomics Research Institute (TGen), Center for Rare Childhood Disorders, Phoenix, AZ, USA. 31. Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA. 32. West Midlands Regional Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK. 33. RILD Wellcome Wolfson Centre, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. 34. North West Thames Regional Genetics Service, Northwick Park Hospital, Harrow, London, UK. 35. IWK Health Centre, Dalhousie University, Halifax, NS, Canada. 36. North West Thames Regional Genetics Service, Northwick Park Hospital, London, UK. 37. Cheshire & Merseyside Regional Genetics Service, Liverpool Women's Hospital, Liverpool, UK. 38. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. 39. Gillette Children's Specialty Healthcare, St. Paul, MN, USA. 40. Children's Minnesota, Minneapolis, MN, USA. 41. Service de génétique clinique, Centre de Référence Maladies Rares «Anomalies du Développement et syndromes malformatifs du Sud-Est", CHU de Clermont-Ferrand, Clermont-Ferrand, France. 42. Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA. 43. Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, USA. 44. Pediatrics-Neurology, Baylor College of Medicine, Houston, TX, USA. 45. Northern Genetics Service-Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK. 46. Institute of Neuroscience, Newcastle University, Framlington Place, Newcastle upon Tyne, UK. 47. Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 48. Division of Metabolic Disorders, Children's Hospital of Orange County (CHOC), Orange, CA, USA. 49. Department of Human Genetics, Emory Universit, Atlanta, GA, USA. 50. Division of Pediatric Neurology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Center, Montreal, QC, Canada. 51. Division of Medical Genetics, Department of Specialized Medicine, McGill University, Montreal, QC, Canada. 52. Child Development Program, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Center, Montreal, QC, Canada. 53. Division of Clinical and Metabolic Genetics, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada. 54. Children's hospital of Los Angeles, Los Angeles, CA, USA. 55. Medical Genetics and Metabolism, Valley Children's Hospital, Madera, CA, USA. 56. CHU Nantes, Service de Génétique Médicale, Nantes, France. 57. INSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France. 58. Institut für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Germany. 59. Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 60. IGBMC, CNRS UMR 7104/INSERM U964/Université de Strasbourg, Illkirch, France. 61. Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA. 62. Department of Surgery, Division of Orthopaedic Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. lefebvrev1@email.chop.edu. 63. INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France. christel.depienne@uni-due.de. 64. Institut für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Germany. christel.depienne@uni-due.de. 65. IGBMC, CNRS UMR 7104/INSERM U964/Université de Strasbourg, Illkirch, France. christel.depienne@uni-due.de.
Abstract
PURPOSE: Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just over two dozen patients with heterozygous genetic alterations involving SOX5, a gene encoding a transcription factor regulating cell fate and differentiation in neurogenesis and other discrete developmental processes. The genetic alterations described so far are mainly microdeletions. The present study was aimed at increasing our understanding of LAMSHF, its clinical and genetic spectrum, and the pathophysiological mechanisms involved. METHODS: Clinical and genetic data were collected through GeneMatcher and clinical or genetic networks for 41 novel patients harboring various types ofSOX5 alterations. Functional consequences of selected substitutions were investigated. RESULTS: Microdeletions and truncating variants occurred throughout SOX5. In contrast, most missense variants clustered in the pivotal SOX-specific high-mobility-group domain. The latter variants prevented SOX5 from binding DNA and promoting transactivation in vitro, whereas missense variants located outside the high-mobility-group domain did not. Clinical manifestations and severity varied among patients. No clear genotype-phenotype correlations were found, except that missense variants outside the high-mobility-group domain were generally better tolerated. CONCLUSIONS: This study extends the clinical and genetic spectrum associated with LAMSHF and consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of intellectual disability, language delay, and other clinical features.
PURPOSE: Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just over two dozen patients with heterozygous genetic alterations involving SOX5, a gene encoding a transcription factor regulating cell fate and differentiation in neurogenesis and other discrete developmental processes. The genetic alterations described so far are mainly microdeletions. The present study was aimed at increasing our understanding of LAMSHF, its clinical and genetic spectrum, and the pathophysiological mechanisms involved. METHODS: Clinical and genetic data were collected through GeneMatcher and clinical or genetic networks for 41 novel patients harboring various types ofSOX5 alterations. Functional consequences of selected substitutions were investigated. RESULTS: Microdeletions and truncating variants occurred throughout SOX5. In contrast, most missense variants clustered in the pivotal SOX-specific high-mobility-group domain. The latter variants prevented SOX5 from binding DNA and promoting transactivation in vitro, whereas missense variants located outside the high-mobility-group domain did not. Clinical manifestations and severity varied among patients. No clear genotype-phenotype correlations were found, except that missense variants outside the high-mobility-group domain were generally better tolerated. CONCLUSIONS: This study extends the clinical and genetic spectrum associated with LAMSHF and consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of intellectual disability, language delay, and other clinical features.
Authors: Allen N Lamb; Jill A Rosenfeld; Nicholas J Neill; Michael E Talkowski; Ian Blumenthal; Santhosh Girirajan; Debra Keelean-Fuller; Zheng Fan; Jill Pouncey; Cathy Stevens; Loren Mackay-Loder; Deborah Terespolsky; Patricia I Bader; Kenneth Rosenbaum; Stephanie E Vallee; John B Moeschler; Roger Ladda; Susan Sell; Judith Martin; Shawnia Ryan; Marilyn C Jones; Rocio Moran; Amy Shealy; Suneeta Madan-Khetarpal; Juliann McConnell; Urvashi Surti; Andrée Delahaye; Bénédicte Heron-Longe; Eva Pipiras; Brigitte Benzacken; Sandrine Passemard; Alain Verloes; Bertrand Isidor; Cedric Le Caignec; Gwen M Glew; Kent E Opheim; Maria Descartes; Evan E Eichler; Cynthia C Morton; James F Gusella; Roger A Schultz; Blake C Ballif; Lisa G Shaffer Journal: Hum Mutat Date: 2012-04 Impact factor: 4.878
Authors: Luke H Hoeppner; Kathryn N Phoenix; Karl J Clark; Resham Bhattacharya; Xun Gong; Tracey E Sciuto; Pawan Vohra; Sandip Suresh; Santanu Bhattacharya; Ann M Dvorak; Stephen C Ekker; Harold F Dvorak; Kevin P Claffey; Debabrata Mukhopadhyay Journal: Blood Date: 2012-06-06 Impact factor: 22.113
Authors: Helen V Firth; Shola M Richards; A Paul Bevan; Stephen Clayton; Manuel Corpas; Diana Rajan; Steven Van Vooren; Yves Moreau; Roger M Pettett; Nigel P Carter Journal: Am J Hum Genet Date: 2009-04-02 Impact factor: 11.025
Authors: Peter Dy; Alfredo Penzo-Méndez; Hongzhe Wang; Carlos E Pedraza; Wendy B Macklin; Véronique Lefebvre Journal: Nucleic Acids Res Date: 2008-04-10 Impact factor: 16.971
Authors: Monkol Lek; Konrad J Karczewski; Eric V Minikel; Kaitlin E Samocha; Eric Banks; Timothy Fennell; Anne H O'Donnell-Luria; James S Ware; Andrew J Hill; Beryl B Cummings; Taru Tukiainen; Daniel P Birnbaum; Jack A Kosmicki; Laramie E Duncan; Karol Estrada; Fengmei Zhao; James Zou; Emma Pierce-Hoffman; Joanne Berghout; David N Cooper; Nicole Deflaux; Mark DePristo; Ron Do; Jason Flannick; Menachem Fromer; Laura Gauthier; Jackie Goldstein; Namrata Gupta; Daniel Howrigan; Adam Kiezun; Mitja I Kurki; Ami Levy Moonshine; Pradeep Natarajan; Lorena Orozco; Gina M Peloso; Ryan Poplin; Manuel A Rivas; Valentin Ruano-Rubio; Samuel A Rose; Douglas M Ruderfer; Khalid Shakir; Peter D Stenson; Christine Stevens; Brett P Thomas; Grace Tiao; Maria T Tusie-Luna; Ben Weisburd; Hong-Hee Won; Dongmei Yu; David M Altshuler; Diego Ardissino; Michael Boehnke; John Danesh; Stacey Donnelly; Roberto Elosua; Jose C Florez; Stacey B Gabriel; Gad Getz; Stephen J Glatt; Christina M Hultman; Sekar Kathiresan; Markku Laakso; Steven McCarroll; Mark I McCarthy; Dermot McGovern; Ruth McPherson; Benjamin M Neale; Aarno Palotie; Shaun M Purcell; Danish Saleheen; Jeremiah M Scharf; Pamela Sklar; Patrick F Sullivan; Jaakko Tuomilehto; Ming T Tsuang; Hugh C Watkins; James G Wilson; Mark J Daly; Daniel G MacArthur Journal: Nature Date: 2016-08-18 Impact factor: 49.962
Authors: Dara Tolchin; Jessica P Yeager; Priya Prasad; Naghmeh Dorrani; Alvaro Serrano Russi; Julian A Martinez-Agosto; Abdul Haseeb; Marco Angelozzi; G W E Santen; Claudia Ruivenkamp; Saadet Mercimek-Andrews; Christel Depienne; Alma Kuechler; Barbara Mikat; Hermann-Josef Ludecke; Frederic Bilan; Gwenael Le Guyader; Brigitte Gilbert-Dussardier; Boris Keren; Solveig Heide; Damien Haye; Hilde Van Esch; Liesbeth Keldermans; Damara Ortiz; Emily Lancaster; Ian D Krantz; Bryan L Krock; Kieran B Pechter; Alexandre Arkader; Livija Medne; Elizabeth T DeChene; Eduardo Calpena; Giada Melistaccio; Andrew O M Wilkie; Mohnish Suri; Nicola Foulds; Amber Begtrup; Lindsay B Henderson; Cara Forster; Patrick Reed; Marie T McDonald; Allyn McConkie-Rosell; Julien Thevenon; Pauline Le Tanno; Charles Coutton; Anne C H Tsai; Sarah Stewart; Ales Maver; Rudolf Gorazd; Olivier Pichon; Mathilde Nizon; Benjamin Cogné; Bertrand Isidor; Dominique Martin-Coignard; Radka Stoeva; Véronique Lefebvre; Cédric Le Caignec Journal: Am J Hum Genet Date: 2020-05-21 Impact factor: 11.025